Earnings summaries and quarterly performance for NEXGEL.
Executive leadership at NEXGEL.
Board of directors at NEXGEL.
Research analysts who have asked questions during NEXGEL earnings calls.
Recent press releases and 8-K filings for NXGL.
BioPorto Announces Preliminary 2025 Financials and 2026 Guidance
NXGL
Earnings
Guidance Update
New Projects/Investments
- BioPorto reported preliminary unaudited revenue of DKK 40.3 million for the 2025 financial year, an 11% increase year-over-year, and an adjusted EBITDA loss of approximately DKK 77 million, both within their latest guidance. The company's cash position as of December 31, 2025, was approximately DKK 55 million.
- For 2026, BioPorto provides guidance targeting total revenue of DKK 48-58 million (20-45% growth) and an adjusted EBITDA loss of DKK 50-60 million (22-35% decrease in loss).
- The company aims to increase active hospitals in the U.S. to over 60 by the end of 2026, driven by NGAL Research Use Only (RUO) sales, following 44 active hospitals at the end of 2025.
- BioPorto is preparing for the clinical validation study for adults, with database lock expected in Q1 2026 and a pre-submission package to the U.S. Food and Drug Administration (FDA) by the end of Q1 2026, with final regulatory submission anticipated by the end of H1 2027.
1 day ago
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NXGL
New Projects/Investments
M&A
- NEXGEL, Inc. announced the spin-off of its drug delivery program into a new entity, NexGelRx, on December 11, 2025.
- NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx for up to $8 million of capital investment.
- NEXGEL will also receive a 5% global royalty in perpetuity on products sold by NexGelRx using its drug delivery technology and will be the exclusive manufacturer of hydrogel for NexGelRx.
Dec 11, 2025, 9:15 PM
NEXGEL Spins Off Drug Delivery Assets into NexGelRx
NXGL
New Projects/Investments
M&A
- NEXGEL has spun off its drug delivery application assets into a new entity, NexGelRx, which will focus exclusively on developing and commercializing prescription (Rx) drug delivery solutions utilizing NEXGEL’s proprietary hydrogel technology.
- NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx, which includes up to $8 million of capital investment.
- NEXGEL will receive a 5% global royalty in perpetuity on products sold by NexGelRx using its drug delivery technology and will be the exclusive manufacturer of hydrogel for NexGelRx.
- This spin-off allows NEXGEL to pursue high-value Rx opportunities without funding its development, while NEXGEL remains focused on contract manufacturing and consumer branded products in the health and beauty space.
Dec 11, 2025, 1:00 PM
NEXGEL Reports Third Quarter 2025 Financial Results
NXGL
Earnings
New Projects/Investments
- NEXGEL reported net revenue of $2.93 million for Q3 2025, which remained flat compared to $2.94 million in Q3 2024, while gross profit increased to $1.24 million (42.4% margin) from $1.16 million (39.3% margin) in Q3 2024.
- The company's Adjusted EBITDA loss narrowed sequentially to ($0.35) million in Q3 2025 from ($0.42) million in Q2 2025, reflecting consistent performance in contract manufacturing and consumer branded products, and operational efficiencies.
- Net loss attributable to NEXGEL stockholders for Q3 2025 was $0.65 million, an improvement from a net loss of $0.69 million in Q3 2024.
- As of September 30, 2025, NEXGEL held a cash balance of $938 thousand and a restricted cash balance of $920 thousand, the latter stemming from $1 million in non-dilutive capital from STADA to support upcoming product launches and marketing efforts.
Nov 12, 2025, 1:06 PM
NEXGEL Reports Q3 2025 Financial Results and Provides Full-Year Guidance
NXGL
Earnings
Guidance Update
Product Launch
- NEXGEL reported revenue of $2.9 million for the third quarter of 2025, which was flat year over year, and achieved a gross profit margin of 42.4%.
- The company's adjusted EBITDA loss continued to narrow sequentially, reaching negative $354,000 in Q3 2025, compared to negative $419,000 in Q2 2025 and negative $500,000 in Q1 2025.
- NEXGEL provided full-year 2025 revenue guidance of between $12 million and $12.5 million and anticipates Q4 2025 to be a record quarter with adjusted EBITDA potentially near break-even.
- Key developments include an agreement with iRhythm to supply Hydrogels for their ZIO ECG heart monitoring system, with first direct orders anticipated in Q4, and an expanded partnership with STADA, which provided $1 million in non-dilutive financing.
- As of September 30, 2025, the company held a cash balance of approximately $938,000 and a restricted cash balance of $920,000.
Nov 11, 2025, 9:30 PM
NEXGEL Reports Third Quarter 2025 Financial Results
NXGL
Earnings
New Projects/Investments
- NEXGEL reported net revenue of $2.93 million for the third quarter of 2025, representing a slight 0.20% decrease compared to $2.94 million in Q3 2024.
- The company's gross profit margin improved to 42.4% in Q3 2025, up from 39.3% in Q3 2024.
- Net loss attributable to NEXGEL stockholders narrowed to $0.65 million in Q3 2025, an improvement from a $0.69 million loss in Q3 2024.
- Adjusted EBITDA was ($0.35) million in Q3 2025, consistent with Q3 2024, and the CEO noted a sequential narrowing of the Adjusted EBITDA loss.
Nov 11, 2025, 9:10 PM
NXGL Reports Strong Q2 2025 Revenue Growth and Details Strategic Partnerships
NXGL
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- NXGL's direct-to-consumer products division generates approximately $8 million annually and the company operates a 16,500 square foot facility in Langhorne, Pennsylvania, utilizing an electron beam accelerator at 18% capacity.
- The company has expanded its consumer health and beauty portfolio through acquisitions like Silly George, which grew from $2 million to a $5.5-$6 million annual run rate since its acquisition in May 2024, and strategic partnerships.
- Key partnerships include a joint venture with STADA, which provided $1 million in non-dilutive capital and expanded to include 9-11 new products for U.S. release starting in Q4 2025. NXGL also partners with Cintas Corporation for Silverseal distribution, with initial shipments in Q4 2024 and Q1 2025, and anticipates significant revenue from AbbVie's Resonic cellulite treatment starting in the second half of 2026.
- NXGL reported over 100% revenue growth in Q2 2025, driven by consumer product sales and contract manufacturing, and is actively developing medical device applications, including an apremilast patch and adhesive solutions for devices like iRhythm's Zio.
Oct 20, 2025, 6:30 PM
NXGL Highlights Strong Q2 Growth, Strategic Partnerships, and Product Expansion
NXGL
Revenue Acceleration/Inflection
Product Launch
M&A
- NXGL reported over 100% revenue growth in Q2, primarily driven by consumer product sales and contract manufacturing.
- The company's direct-to-consumer products division generates $8 million annually, with the recently acquired Silly George beauty brand growing from $2 million to a $5.5 million to $6 million annual run rate.
- NXGL has established significant partnerships, including a joint venture with Stada, which provided $1 million in non-dilutive capital and plans to launch 9-11 additional products, and a distribution agreement with Cintas Corporation for SilverSeal.
- Further collaborations include a partnership with AbbVie for its Resonic cellulite treatment, with initial orders expected shortly, and iRhythm, which is using NXGL's gel as an adhesive for its Zayo device.
Oct 20, 2025, 6:30 PM
Quarterly earnings call transcripts for NEXGEL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more